5439042026-10-265439042026-10-262026-10-265439042026-10-262026-10-26AmalgamatedEntityDomain15439042026-10-26AmalgamatedEntityDomain15439042026-10-262026-10-26AmalgamatedEntityDomain25439042026-10-26AmalgamatedEntityDomain25439042026-10-262026-10-26AmalgamatedEntityDomain35439042026-10-26AmalgamatedEntityDomain3xbrli:purexbrli:shares543904Mankind Pharma LimitedMANKINDNOTLISTEDINE634S01028NewAmalgamation/ Mergertrue2026-10-2614:45:002026-10-26Prolijune Lifesciences Private Limited (Transferor Company 1)TransferorSubsidiaryPaid-up share capital : 0.49 crores Turnover: 1.78 crores Net Worth: 20.62 crores49145710000491457100000000Pavi Buildwell Private Limited (Transferor Company 2)TransferorSubsidiaryPaid-up share capital : 2.01 crores Turnover:- 0 Net Worth: (17.96) crores20100010000201000100000000Mankind Pharma LimitedTransferorListed Entity (self)Paid-up share capital : 41.30 crores Turnover: 10,421.18 crores Net Worth: 16396.94 crores2999606120.731130844780.23004130450900.962999606120.731130844780.27004130450901true2026-10-262026-10-26falsetrueBoth the Transferor Companies are the wholly-owned subsidiaries of the Transferee Company. However, Ministry of Corporate Affairs has clarified vide its General Circular No. 30/2014 dated July 17, 2014 that transactions arising out of compromise, arrangements and amalgamations dealt under specific provisions of the Companies Act, 2013, will not fall within the purview of related party transaction in terms of Section 188 of the Companies Act, 2013. Further, pursuant to Regulation 23(5)(b) of the Listing Regulations, the provisions relating to related party transactions are not applicable to transactions entered into between a holding company and its wholly-owned subsidiary.trueProlijune Life Sciences Private Limited is engaged in the business of leasing and providing on lease all types of buildings and real estate for industrial, commercial or residential purposes. Pavi Buildwell Private Limited is engaged in the business of real estate development. Mankind Pharma Limited is engaged in the business of research, development, manufacturing, marketing and distribution of pharmaceutical formulations across various acute and chronic therapeutic segments. It also has a portfolio of specialty and super-specialty pharmaceutical products, supported by its manufacturing and research and development capabilities. The Transferor Companies are wholly owned subsidiaries of the Transferee Company, a listed company, and thus part of same Group. The proposed Scheme of Amalgamation aims to simplify and rationalise the existing group structure by amalgamating the Transferor Companies with and into the Transferee Company, thereby reducing the number of legal entities within the Group and creating a more streamlined and efficient corporate structure. The amalgamation is expected to facilitate effective management, optimum utilisation of resources, and administrative and operational efficiencies. It will also enable better consolidation and allocation of financial resources, achieve managerial and financial synergies, and enhance overall organisational efficiency, thereby contributing to long-term value creation for the stakeholders.OthersPursuant to the Scheme of Arrangement, no new equity shares shall be issued, nor shall any consideration be paid in cash or otherwise by the Transferee Company, since both the Transferor Company 1 and Transferor Company 2 are the wholly-owned subsidiaries of the Transferee Company. Considering the Scheme does not envisage the issuance of any fresh shares or payment of any consideration to the shareholders of either Transferor Company 1 or Transferor Company 2, the requirement for determination of a Share Exchange Ratio and preparation of a Valuation Report for such purpose is not applicable in the present Scheme.There will be no change in the shareholding pattern of the Company as no shares are being issued pursuant to the Scheme.In terms of Regulation 37(6) of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, and Joint Standard Operating Procedure (SOP) dated July 31, 2025 for application filed under regulation 59A of Listing Regulations, the Scheme, being an amalgamation of wholly owned subsidiaries with their holding company, is exempt from the requirement of obtaining a No-Objection Letter from the Stock Exchanges. However, as per requirement laid down in above provisions, the Company will be fileing the Scheme of Arrangement with the Stock Exchanges for disclosure purposes. Further, the pre and post shareholding of the Companies mentioned above is on fully diluted basis.